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Introduction
Febrile neutropenia (FN) in cancer patients is a common complica-
tion related to antineoplastic therapy, such as chemotherapy and
radiotherapy. It is a high risk factor for developing serious bacterial
infections that can result in fatal outcomes. Mortality has been reported
to be higher in FN patients with bacteremia than in those without
bacteremia [1]. Recently, more cancer patients receive chemotherapy
in outpatient settings, so the number of patients that visit the emergency
department (ED) with complications related to antineoplastic therapy is
increasing [2]. Therefore an immediate and appropriate strategy for this
population in ED is required to reduce treatment delays and improve
outcomes.
The early diagnosis of bacterial infection among patients with FN is
challenging. Focus of infection is uncertain, and only a few clinical
signs such as fever, headache, and hypotension may indicate bacterial
infections in many cases of FN [3]. Efforts to predict bacteremia have
Purpose
Procalcitonin (PCT) and C-reactive protein (CRP) are well known inflammatory markers. This
study was designed to determine whether PCT and CRP are useful as early diagnostic
markers for bacteremia in cancer patients with febrile neutropenia (FN) in the emergency
department (ED).
Materials and Methods
In this retrospective study, 286 episodes of FN in the ED were consecutively included
between June 2009 and August 2010. From medical records, clinical characteristics in-
cluding PCT and CRP were extracted and analyzed.
Results
Bacteremia was identified in 38 (13.3%) of the 286 episodes. The median values of PCT (2.8
ng/mL vs. 0.0 ng/mL, p=0.000) and CRP (15.9 mg/dL vs. 5.6 mg/dL, p=0.002) were significantly
higher in the group with bacteremia compared to the group without bacteremia. In univariate
analysis, elevated PCT (ĥ0.5 ng/mL) and CRP (ĥ10 mg/dL) as well as older age, hypoten-
sion, tachycardia, tachypnea, and high body temperature were significantly associated with
bacteremia. On multivariate analysis, elevated PCT (ĥ0.5 ng/mL) (odds ratio [OR], 3.6; 95%
confidence interval [CI], 1.4 to 9.2; pģ0.01) and tachypnea (OR, 3.4; 95% CI, 1.4 to 8.5; pģ0.01)
were independent early diagnostic markers for bacteremia in FN patients. The area under
the curve of PCT was 74.8% (95% CI, 65.1 to 84.6%) and that of CRP was 65.5% (95% CI, 54.8
to 76.1%). With a PCT cut-off value of 0.5 ng/mL, sensitivity and specificity were 60.5% and
82.3%, respectively, while the sensitivity and specificity were 57.6% and 67.3%, respectively,
with a CRP cutoff of 10 mg/dL.
Conclusion
These findings suggest that PCT is a useful early diagnostic marker for the detection of
bacteremia in FN at the ED and has better diagnostic value than CRP. 
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been made, but their sensitivity and specificity have been poor [4].
Even though blood cultures are the gold standard for the diagnosis of
bacteremia [5], obtaining and testing these is time-consuming and their
results are not available immediately in the ED. Therefore, a predictive
tool to diagnose bacterial infections in FN is crucial for early diagnosis
in the ED.
Several inflammatory markers have been studied for the diagnosis of
infection. Among them, C-reactive protein (CRP) is frequently used
and is a good marker of infection but it rarely distinguishes between
bacterial and viral infection [6]. Procalcitonin (PCT) is a prohormone
of calcitonin secreted from C-cells of the thyroid gland, and has been
proposed as a candidate marker for diagnosis of active bacterial
infections [7]. Serum PCT concentration in healthy individuals is low,
but raises during septic conditions, especially when related to bacterial
infections [8].
In this study, we aimed to evaluate the usefulness of PCT and CRP
as early diagnostic markers of bacteremia in cancer patients with
chemotherapy-related FN in the ED.
Materials and Methods
Subjects enrolled in this study were adult cancer patients (16 years or
older) with chemotherapy-associated FN who visited the ED of a
university-affiliated tertiary referral medical center, between June 2009
and August 2010. Clinical data were retrospectively extracted from the
electronic medical records.
Fever was defined as a single oral temperature of 38.3 or a
temperature of 38.0 for1 hour, and neutropenia was defined as
a neutrophil count of ģ500 cells/mm
3, or a count of ģ1,000 cells/mm
3
with a predicted decrease toģ500 cells/mm
3[9].
Laboratory data were obtained with complete blood count, serum
creatinine, blood urea nitrogen, aspartate transaminase, and alanine
transaminase (ALT) as well as PCT and CRP, at the time of admission
to ED.
All statistical data were analyzed with SPSS ver. 12.0.1 (SPSS Inc.,
Chicago, IL). The Chi-square test and Student’s t-test were used for
univariate analysis. The Wilcoxon rank sum test for continuous data
was used to screen for admission parameters potentially associated
with final outcomes. Median values with interquartile range were
calculated for inflammatory markers including PCT and CRP. For
univariate analysis, age was categorized by the median value and
clinical measurements were classified as hypotension (systolic blood
pressure [SBP]ģ90 mm Hg), tachycardia (pulse rateĥ120 beats/min),
tachypnea (respiratory rateĥ24 breathes/min), and high body
temperature (ĥ39). PCT were grouped by three cut-off values of
0.1, 0.5, and 1.0 ng/mL, and similarly CRP by cutoff values of 5, 10,
and 20 mg/dL. All the categorical variables were compared using Chi-
square analysis. Parameters considered significantly associated with a
high risk of bacteremia were selected in univariate analysis, and the
logistic regression for multivariate analysis was calculated for odds
ratio (OR) and 95% confidence interval (CI). Diagnostic values for
bacteremia of PCT and CRP were calculated by analyzing the receiver
operating characteristic (ROC) curves. p-valuesģ0.05 were con-
sidered to be statistically significant. 
Results
1 Baseline characteristics of the overall population
A total of 286 patients were included as the study population,
including 239 (83.6%) from solid tumors and 47 (16.4%) from
hematologic malignancies. Among solid tumors, breast cancer was the
most common in 94 followed by gastrointestinal cancer in 68 and lung
cancer in 37 patients. Hematologic malignancies consisted of 37
lymphoma, 4 myelodysplastic syndromes, and 3 leukemia patients.
The median age of patients was 54 years and females were dominant in
the population (male : female=1 : 1.25).
As shown in Table 1, bacteremia was detected in 38 episodes
(13.3%). In comparison between groups with and without bacteremia,
the bacteremia group showed significantly higher rates of pulse (115
beats/min vs. 108 beats/min, p=0.01) and respiration (22 breaths/min
vs. 20 breaths/min, pģ 0.01) than the non-bacteremia group whereas
SBP (114 mm Hg vs. 117 mm Hg) and body temperature (38.5 vs.
38.4) were not significantly different between the two groups (pĥ
0.05, each). The bacteremia group had poorer laboratory findings than
the non-bacteremia group, although there was no significant difference
in absolute neutrophil count (ANC) and ALT. In the same way, PCT
and CRP showed much higher levels in the bacteremia group com-
pared to the non-bacteremia group (the median value of PCT, 2.75
ng/mL vs. 0.00 ng/mL, pģ0.01; the median value of CRP, 15.9
mg/dL vs. 5.6 mg/dL, pģ0.01).
2 Comparison of early clinical features between FN
groups with and without bacteremia
The majority of patients in the bacteremia group were older than
those in the non-bacteremia group (68% vs. 44%, pģ0.01). Two
groups showed difference in gender distribution but this finding was
not significant. Hypotension (24% vs. 4%), tachycardia (42% vs.
19%), tachypnea (37% vs. 9%), and high body temperature (42% vs.
21%) were reported more commonly and significantly in the
bacteremia group than in the non-bacteremia group (pģ0.01 for all).
As shown in Table 2, in all comparisons of various cut-off values of
PCT, the bacteremia group had higher PCT levels than the non-
bacteremia group with statistical significance. On the other hand, in a
category of CRP with the cut-off value of 5 mg/dL, there was no
significant difference between bacteremia and non-bacteremia groups
(68% vs. 52%, p=0.08), even though significant differences were
observed in other categories of CRP with the cut-off value of 10 mg/dLCancer Res Treat. 2011;43(3):176-180
178 CANCER  RESEARCH AND  TREATMENT
(58% vs. 33%, pģ0.01) and 20 mg/dL (37% vs. 12%, pģ0.01)
(Table 2). On multivariate analysis, PCT with a cutoff value of 0.5
ng/mL (OR, 3.6; 95% CI, 1.4 to 9.2; pģ0.01) and tachypnea (OR, 3.4;
95% CI, 1.4 to 8.5; pģ0.01) were independent early diagnostic
markers for bacteremia in FN patients at ED (Table 3). 
3 Diagnostic accuracy of PCT and CRP for bacteremia in FN
The ROC curves of PCT and CRP are shown in Fig. 1. The area
under the curve (AUC) of PCT was 74.8% (95% CI, 65.1 to 84.6%)
Characteristics All Bacteremia (+) Bacteremia (-) p-value
No. of patients (%)   286 38 (13.3) 248 (86.7)
Age (range, yr) 54 (42-64) 62 (24-91) 53 (16-82) ģ0.01
Male gender 127 (44.4) 22 (57.9)  105 (42.3)  0.07
Underlying malignancy 0.24
Solid tumor  239 (84)                                    29/239 (12)                           210/239 (88)
Hematologic malignancy 47 (16) 9/47 (19)                                          38/47 (81)
Vital signs
SBP (mm Hg) 116 (104-128) 114 (91-126)  117 (105-128)  0.09
Pulse rate (beats/min) 108 (98-118) 115 (103-135)  108 (98-118)  0.01  
Respiratory rate (breaths/min) 20 (20-22) 22 (20-24) 20 (20-20)  ģ0.01
Body temperature () 38.4 (36.3-38.9) 38.5 (38.1-39.2)  38.4 (38.1-38.8)  0.18
Laboratory findings
ANC (/mm
3)  130 (40-370) 90 (20-363) 140 (41-383) 0.20
Hemoglobin (g/dL)  10.6 (9.3-11.6) 9.8 (8.6-10.6) 10.7 (9.4-11.7) ģ0.01 
Platelet (10
3/mm
3)  126.5 (81.5-188.0) 68.0 (28.0-126.3) 136.5 (92.0-197.3) ģ0.01
AST (IU/L) 26 (20-37) 39 (24-54) 25 (20-35) ģ0.01
ALT (IU/L)  23 (16-36) 28 (16-53) 23 (16-53) 0.08
BUN (mg/dL)  11 (7-16) 18 (14-31) 10 (7-15) ģ0.01
Creatinine (mg/dL)  0.7 (0.6-0.9) 0.6 (0.7-1.3) 0.7 (0.6-0.8) ģ0.01
CRP (mg/dL) 5.8 (2.6-14.0) 15.9 (3.6-26.0) 5.6 (2.5-12.7) ģ0.01
PCT (ng/mL) 0.05 (0.00-0.36) 2.8 (0.04-20.8) 0.0 (0.00-0.18) ģ0.01
Table 1. Baseline characteristics in the overall study population 
Values are presented as number (%) or median (IQR). By the Shapiro-Wilk test, all variables in categories of vital signs and laboratory findings were not normally distributed. The
Wilcoxon’s rank-sum test was used to calculate variables in each category. SBP, systolic blood pressure; ANC, absolute neutrophil count; AST, aspartate transaminase; ALT, alanine
transaminase; BUN, blood urea nitrogen; CRP, C-reactive protein; PCT, procalcitonin; IQR, interquartile range.
Table 3. Multivariate analysis for bacteremia in febrile neutropenia
patients
Odds ratio (95% CI) p-value
Ageĥmedian age of 54 yr  1.7 (0.8-3.9) 0.19 
SBPģ90 mm Hg 2.4 (0.8-7.7) 0.14 
Pulse rateĥ120 beats/min 1.8 (0.8-4.0) 0.18 
Respiratory rateĥ24 breaths/min 3.4 (1.4-8.5) ģ0.01 
Body temperatureĥ39 1.6 (0.7-3.5) 0.31 
PCT > 0.5 ng/mL 3.6 (1.4-9.2) ģ0.01 
CRP > 10 mg/dL 0.8 (0.34-2.1) 0.71 
CI, confidence interval; SBP, systolic blood pressure; PCT, procalcitonin; CRP, C-
reactive protein.
Table 2. Comparison of early clinical features between febrile neu-
tropenia groups with and without bacteremia




Ageĥmedian age of 54 yr 26 (68) 108 (44) ģ0.01
Male gender  22 (58) 105 (42) 0.08
Clinical measurements
SBPģ90 mm Hg 9 (24) 10 (4) ģ0.01
Pulse rateĥ120 beats/min 16 (42) 46 (19) ģ0.01
Respiratory rateĥ24 breaths/min 14 (37) 21 (9) ģ0.01
Body temperatureĥ39 16 (42) 53 (21) ģ0.01
Inflammatory markers 
PCT (ng/mL)
ĥ0.1  27 (71) 84 (34) ģ0.01
ĥ0.5  23 (61) 44 (18) ģ0.01
ĥ1.0  22 (58) 28 (11) ģ0.01
CRP (mg/dL)
ĥ5 26  (68) 130  (52) 0.08
ĥ10  22 (58) 81 (33) ģ0.01
ĥ20  14 (37) 29 (12) ģ0.01
Values are presented as number (%). SBP, systolic blood pressure; PCT, pro-
calcitonin; CRP, C-reactive protein.Dae Yong Kim, et al_Bacteremia in Febrile Neutropenia
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while the AUC of CRP was 65.5% (95% CI, 54.8 to 76.1%),
representing higher diagnostic accuracy of PCT to predict bacteremia
than the accuracy of CRP (pģ0.05). With a PCT cutoff of 0.5 ng/mL,
sensitivity and specificity of PCT were 60.5% and 82.3%, respectively.
CRP with a cutoff of 10 mg/dL showed sensitivity and specificity of
CRP as 57.6% and 67.3%, respectively. Table 4 shows sensitivity and
specificity, as well as positive and negative likelihood ratios for PCT
and CRP.
Discussion
FN with infection is a medical emergency that requires rapid
diagnosis and intervention as soon as possible. Localizing signs and
symptoms of infection are minimal or often absent and the progression
of infection can be rapid in FN patients [9]. Therefore, an early
diagnostic test to predict bacteremia in FN would be of great value by
providing physicians with more definite evidence of the etiology of
fever; especially in the ED where the first point of care has to be done.
On account of difficulties in diagnosis of bacterial infection in the
FN, attempts to improve accuracy and rapidity of diagnosis of infection
have been made through efforts on biomarkers [10]. Among various
biomarkers, PCT and CRP have been considered useful [11]. In pre-
vious reports on PCT and CRP, PCT was shown to be more strongly
associated with documented bacterial infection in FN patients [12].
PCT increased earlier in bacterial infection and returned to the normal
range more quickly than CRP. In healthy individuals, PCT
concentrations were below the detection limit but levels increased with
increasing severity of the inflammatory response to bacterial infection
[13]. In comparison with PCT, there was a wider overlap of CRP
levels between groups with and without bacteremia. On multivariate
analysis, PCT was an independent, useful marker whereas CRP was
not significant in predicting bacteremia. Similarly, the ROC curve
showed superior sensitivity and specificity of PCT over CRP. A cut-off
value of serum PCT to discriminate bacteremia from non-bacterial
infection was adopted in this study as proposed previously [14,15].
PCT0.5 ng/mL showed statistical significance in predicting
bacteremia in FN patients. On the basis of the reported PCT values in
FN, PCT valuesģ0.5 ng/mL were less likely to occur in patients with
bacteremia. For a cut-off value of CRP, 10 mg/dL was used as
proposed in the previous study [16].
In this study, the incidence of bacteremia was 13.3% and variables
including age, initial vital signs, laboratory data except ANC and ALT,
PCT and CRP, were significantly different between groups with and
without bacteremia. However, to discover factors related with un-
revealed bacteremia in early phase and to evaluate the usefulness of
inflammatory markers, vital signs recorded initially at the ED and
inflammatory markers, including PCT and CRP, at the time of ad-
mission were analyzed. As the result, tachypnea as well as PCT was
significant as an early diagnostic marker for bacteremia. In the study by
Bossink et al. [17], among the Systemic Inflammatory Response
Syndrme (SIRS) criteria, tachypnea was the only factor that signi-
ficantly predicted shock development in febrile patients using
multivariate analysis. Considering that rapid respiratory rate and eleva-
ted PCT were independently and strongly associated with bacteremia,
physicians should pay more attention to FN patients who present these
characteristics.
Origins of inflammatory PCT are controversial since the production
of PCT in the infection phase is not related to thyroid tissues [18]. The
exact site of production during sepsis has not been identified, but it has
been demonstrated that immunoreactive cells including neutrophils
were possible sources of PCT production [19]. Therefore, concerns
have been raised about possible impairment of PCT production in
patients with neutropenia. However, other studies have demonstrated
higher PCT levels in FN patients with documented bacterial infections
[20], and our study also supported the plausibility of PCT as a reliable
marker for bacterial infection in FN.











0.6 1.0 0.4 0.8
74.8% (94% CI, 65.1 to 84.6%) PCT
CRP 65.5% (94% CI, 54.8 to 76.1%)
PCT
CRP
Fig. 1. Receiver operating characteristic (ROC) curves of procal-
citonin (PCT) and C-reactive protein (CRP). The areas under the
ROC curves of PCT and CRP were 74.8% and 65.5%, respectively.
CI, confidence interval. 







ĥ0.1 71.1 66.1 2.1 0.4
ĥ0.5 60.5 82.3 3.4 0.5
ĥ1.0 57.9 88.7 3.8 0.7
CRP (mg/dL) 
ĥ5 68.4 47.6 1.3 0.7
ĥ10 57.6 67.3 1.8 0.6
ĥ20 36.8 88.3 3.1 0.7
PCT, procalcitonin; CRP, C-reactive protein; LR, likelihood ratio.Cancer Res Treat. 2011;43(3):176-180
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that PCT kinetics were more valuable to assess prognosis in infectious
diseases [21]. In this study, however, the levels of PCT were evaluated
only once at the time of admission at the ED. Another limitation is the
heterogeneity of the cancer population. Cancer patients have great
variation in the degree of immunosuppression and long-term survival.
The majority of patients enrolled in this study were with solid tumors.
Patients with hematologic malignancies are more likely to be
immunocompromised than patients with solid organ malignancy and
are at high risk of sepsis and have worse prognosis compared to solid
tumors [22].
Limitation of PCT is that PCT only reflects systemic manifestation
of bacterial infection. PCT may not or may only slightly increase when
infection remains in a localized tissue with no systemic manifestations
[23]. In patients with localized infections without signs of systemic
manifestation, therapeutic measures such as antibiotics or surgical
intervention may be necessary despite of normal PCT levels. Although
elevated PCT values during severe infections may decrease to very low
levels with appropriate therapy, this does not always indicate complete
eradication of the infection but merely that generalization of the
infection or the septic response is under control. Continuation of
antibiotic therapy or surgical measures may be necessary until all
clinical signs of infection have disappeared [13].
Conclusion
Bacteremia were detected in 13.3% of enrolled episodes of FN.
Serum PCT concentration were significantly higher in patients with
bacteremia. In a multivariate analysis, tachypnea and elevated PCT
were independently and significantly associated with bacteremia.
These findings suggest that PCT is a useful early diagnostic marker
to detect bacteremia in cancer patients with FN and has better diag-
nostic value than CRP. It is recommended to establish an early
treatment strategy to prevent complications of bacterial infection in FN
patients with high serum PCT concentration in the ED.
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